Eli Lilly Alzheimer’s Drug Trial Delivers 40% Slowdown in Cognitive Decline: Phase 3 Results Spark FDA Fast-Track Hopes
Eli Lilly's phase 3 trial for new Alzheimer's drug shows 40% slowdown…
CRISPR Breakthrough: UC Berkeley Gene Editing Trial Achieves 95% Symptom Reduction in Sickle Cell Patients
UC Berkeley's CRISPR trial for sickle cell disease achieves 95% symptom reduction,…
Breakthrough CRISPR Gene Editing Trial Achieves 95% Cure Rate for Sickle Cell Disease in Adults
Vertex Pharmaceuticals' Phase III CRISPR trial cures 95% of adult sickle cell…
CRISPR Breakthrough: Gene Editing Cures Rare Muscular Dystrophy in Landmark Human Trial at UC Berkeley
UC Berkeley's CRISPR trial has cured a rare muscular dystrophy in patients,…
CRISPR Breakthrough: First Successful Gene Editing Cure for Sickle Cell Disease in US Clinical Trial
In a medical milestone, CRISPR gene editing has cured sickle cell disease…
Breakthrough: CRISPR Gene Editing Cures Sickle Cell Disease in Landmark Phase 3 Trials
A CRISPR gene editing therapy has cured sickle cell disease in phase…
CRISPR Breakthrough: Johns Hopkins Clinical Trial Cures Rare Genetic Disease in Adults for the First Time
Johns Hopkins' CRISPR clinical trial achieves first full cure for rare genetic…
CRISPR Gene Editing Achieves First-Ever Cure for Rare Genetic Blood Disorder in Phase 3 Clinical Trial
In a historic first, CRISPR gene editing has cured beta-thalassemia in Phase…
CRISPR Breakthrough: UC Berkeley Trial Cures Rare Genetic Blood Disorder in First Human Success
UC Berkeley's CRISPR trial achieves complete remission of rare ATTR blood disorder…
CRISPR Breakthrough: First Human Trial Successfully Cures Rare Genetic Disease with No Side Effects
In a medical first, a Boston biotech firm cures Leber congenital amaurosis…
